Assessment of DNA-PKcs kinase activity by quantum dot-based microarray.
Florian LafontNizar AyadiCathy CharlierPierre WeigelIgor R NabievHouda Benhelli-MokraniFabrice FleuryPublished in: Scientific reports (2018)
Therapeutic efficacy against cancer is often based on a variety of DNA lesions, including DNA double-strand breaks (DSBs) which are repaired by homologous recombination and non-homologous end joining (NHEJ) pathways. In the past decade, the functions of the DNA repair proteins have been described as a potential mechanism of resistance in tumor cells. Therefore, the DNA repair proteins have become targets to improve the efficacy of anticancer therapy. Given the central role of DNA-PKcs in NHEJ, the therapeutic efficacy of targeting DNA-PKcs is frequently described as a strategy to prevent repair of treatment-induced DNA damage in cancer cells. The screening of a new inhibitor acting as a sensitizer requires the development of a high-throughput tool in order to identify and assess the most effective molecule. Here, we describe the elaboration of an antibody microarray dedicated to the NHEJ pathway that we used to evaluate the DNA-PKcs kinase activity in response to DNA damage. By combining a protein microarray with Quantum-Dot detection, we show that it is possible to follow the modification of phosphoproteomic cellular profiles induced by inhibitors during the response to DNA damage. Finally, we discuss the promising tool for screening kinase inhibitors and targeting DSB repair to improve cancer treatment.
Keyphrases
- dna repair
- dna damage
- circulating tumor
- cell free
- single molecule
- oxidative stress
- dna damage response
- high throughput
- nucleic acid
- stem cells
- circulating tumor cells
- tyrosine kinase
- drug delivery
- endothelial cells
- bone marrow
- papillary thyroid
- single cell
- mesenchymal stem cells
- replacement therapy
- cell therapy
- diabetic rats